NEWS

NEWS

News

NantKwest and NantCell Announce FDA Authorization for the NANT Cancer Vaccine Clinical Trials, the First Novel Combination of Innate and Adaptive Immunotherapy in Patients with Pancreatic Cancer

The NANT Cancer Vaccine, The First Simultaneous Combination of Off the Shelf Natural Killer Cells (NK) With Endogenous Adaptive Dendritic, T Cell and NK Cell Activation.   Personalized Molecular Informed Therapy with NantHealth's GPS Cancer as The Complementary...

read more

Archives

Media Contact:

Jen Hodson
NantKwest
Telephone: 562-397-3639
Email: Press@NantKwest.com